维布妥昔单抗联合化疗治疗32例恶性淋巴瘤的临床观察  

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy

作　　者：柴笑菲 乔泓涵 张蕾[1] 李鑫[1] 李玲[1] 王新华[1] 付晓瑞[1] 张旭东[1] 孙振昌[1] 南飞飞[1] 张明智[1] CHAI Xiaofei;QIAO Honghan;ZHANG Lei;LI Xin;LI Ling;WANG Xinhua;FU Xiaorui;ZHANG Xudong;SUN Zhenchang;NAN Feifei;ZHANG Mingzhi(Department of Oncology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤内科,郑州450052

出　　处：《肿瘤防治研究》2023年第3期288-292,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(81970184,82170183);河南省科技厅项目(182102310114)。

摘　　要：目的回顾性分析维布妥昔单抗联合化疗治疗恶性淋巴瘤的临床疗效和安全性。方法收集32例CD30阳性淋巴瘤患者资料,其中霍奇金淋巴瘤14例,弥漫大B细胞淋巴瘤2例,成熟T/NK细胞淋巴瘤16例。所有患者均接受化疗联合维布妥昔单抗的治疗至少2周期,每2个周期结束后依据Lugano标准进行疗效评价。结果4周期治疗后完全缓解率为22%,总缓解率为50%。1~2级毒性16例(50.0%),3级及以上毒性16例(50.0%)。最常见的不良反应是中性粒细胞减少(50.0%)、肺炎(46.9%)、贫血(43.8%)。最常见的3级及以上不良反应是肺炎(18.8%)和发热(12.5%)。4例因严重不良反应停止使用维布妥昔单抗。结论维布妥昔单抗治疗复发难治性CD30阳性霍奇金淋巴瘤及外周T细胞淋巴瘤的疗效确切,总体安全性尚可。Objective To retrospectively evaluate the clinical efficacy and safety of brentuximab vedotin(BV)combined with chemotherapy in the treatment of malignant lymphoma.Methods We collected the data of 32 lymphoma patients with CD30-positive status,including 14 cases of Hodgkin’s lymphomas,2 cases of diffuse large B-cell lymphomas,and 16 cases of mature T/NK cell lymphomas.Chemotherapy combined with BV was administered to all patients for a minimum of two cycles.The efficacy of the treatment was evaluated according to Lugano criteria every two cycles.Results Complete response rate and overall response rate after four cycles of treatment were 22%and 50%,respectively.Sixteen cases(50.0%)had grades 1 and 2 toxicity,and 16 cases(50.0%)had grade 3 toxicity or higher.The most common adverse events were neutropenia(50.0%),pneumonia(46.9%),and anemia(43.8%).The most common grade 3 or higher adverse events were pneumonia(18.8%)and febrile neutropenia(12.5%).Four patients discontinued brentuximab vedotin because of severe adverse events.Conclusion BV is effective in treating relapsed and refractory CD30-positive Hodgkin’s lymphoma and peripheral T-cell lymphoma,and its overall safety is acceptable.

关 键 词：维布妥昔单抗 靶向抗体-药物偶联物 淋巴瘤 预后 

分 类 号：R733.4[医药卫生—肿瘤]